Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.

Paulukonis ST, Eckman JR, Snyder AB, Hagar W, Feuchtbaum LB, Zhou M, Grant AM, Hulihan MM.

Public Health Rep. 2016 Mar-Apr;131(2):367-75.

2.

Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P.

ScientificWorldJournal. 2012;2012:949535. doi: 10.1100/2012/949535. Epub 2012 Aug 1. Review. Erratum in: ScientificWorldJournal. 2013;2013:861251.

3.

Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions.

Wahl SK, Garcia A, Hagar W, Gildengorin G, Quirolo K, Vichinsky E.

Transfusion. 2012 Dec;52(12):2671-6. doi: 10.1111/j.1537-2995.2012.03659.x. Epub 2012 Apr 23.

PMID:
22519830
4.

A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.

Kutlar A, Ataga KI, McMahon L, Howard J, Galacteros F, Hagar W, Vichinsky E, Cheung AT, Matsui N, Embury SH.

Am J Hematol. 2012 May;87(5):536-9. doi: 10.1002/ajh.23147. Epub 2012 Apr 10. Review.

5.

The third described case of transfusion-transmitted Babesia duncani.

Bloch EM, Herwaldt BL, Leiby DA, Shaieb A, Herron RM, Chervenak M, Reed W, Hunter R, Ryals R, Hagar W, Xayavong MV, Slemenda SB, Pieniazek NJ, Wilkins PP, Kjemtrup AM.

Transfusion. 2012 Jul;52(7):1517-22. doi: 10.1111/j.1537-2995.2011.03467.x. Epub 2011 Dec 13.

PMID:
22168221
6.

A tribute to Thomas Roosevelt Punnett, Jr. (1926-2008).

Hagar W, Punnett H, Punnett L, Govindjee.

Photosynth Res. 2011 Oct;110(1):1-7. doi: 10.1007/s11120-011-9695-4. Epub 2011 Oct 11.

PMID:
21986934
7.

A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.

Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L.

Br J Haematol. 2011 Jun;153(5):655-63. doi: 10.1111/j.1365-2141.2010.08480.x. Epub 2011 Apr 8.

8.

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).

Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW; ICA-17043-10 Study Investigators.

Br J Haematol. 2011 Apr;153(1):92-104. doi: 10.1111/j.1365-2141.2010.08520.x. Epub 2011 Feb 17.

PMID:
21323872
9.

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up.

Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699.

10.

Irbesartan in patients with heart failure and preserved ejection fraction.

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators.

N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11.

11.

Advances in clinical research in sickle cell disease.

Hagar W, Vichinsky E.

Br J Haematol. 2008 May;141(3):346-56. doi: 10.1111/j.1365-2141.2008.07097.x. Epub 2008 Mar 12. Review.

PMID:
18341629
12.

Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.

Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, Klings ES.

Blood. 2008 Jan 1;111(1):402-10. Epub 2007 Sep 11.

13.

Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression.

Jenkins ZA, Hagar W, Bowlus CL, Johansson HE, Harmatz P, Vichinsky EP, Theil EC.

Pediatr Hematol Oncol. 2007 Jun;24(4):237-43.

PMID:
17613866
14.

Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload.

Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W, Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E; Multi-Center Study of Iron Overload Research Group.

Am J Hematol. 2007 Apr;82(4):255-65.

15.

Long-term use of hydroxyurea for sickle cell anemia.

Hagar W.

JAMA. 2003 Aug 13;290(6):753; author reply 754. No abstract available.

PMID:
12915424
16.

Liver ferritin subunit ratios in neonatal hemochromatosis.

Hagar W, Vichinsky EP, Theil EC.

Pediatr Hematol Oncol. 2003 Apr-May;20(3):229-35.

PMID:
12637219
17.

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP.

Am J Respir Crit Care Med. 2003 Jul 1;168(1):63-9. Epub 2003 Mar 5.

PMID:
12626350
18.

Diseases of iron metabolism.

Hagar W, Theil EC, Vichinsky EP.

Pediatr Clin North Am. 2002 Oct;49(5):893-909. Review.

PMID:
12430618
19.

Comparing and assessing acid rain-sensitive ponds.

Hagar WG, Crosby BA, Stallsmith BW.

J Hazard Mater. 2000 May 29;74(1-2):125-31.

PMID:
10781722
20.

Manganese toxicity to chlorophyll synthesis in tobacco callus.

Clairmont KB, Hagar WG, Davis EA.

Plant Physiol. 1986 Jan;80(1):291-3.

Supplemental Content

Loading ...
Support Center